The possibility of ribavirin resistance when used without interferon could be a factor. There's also a moral hazard issue to the FDA approving a combo that works in half the patients and GILD profiting twice upon retreatment. There's no competition in these genotypes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.